Concepedia

Dirk Heerwegh

DH

Statistics

Publications

38

Citations

3.7K

H-Index

26

Active since

2002

Affiliations

KU Leuven(Current)

Janssen (Netherlands)

Janssen (Belgium)

Fred Hutch Cancer Center

Beth Israel Deaconess Medical Center

Dirk Heerwegh is an author at KU Leuven specializing in infectious diseases, vaccinology, and veterinary medicine.

Publications per year

2002–2023

38

Publications

38

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev et al. · New England Journal of Medicine · 2021 · 1.2K citations · Full text

, , +16

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter, Jingyou Yu, Jinyan Liu et al. · Nature · 2021 · 352 citations · Full text

, , +16

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson, Mathieu Le Gars, Jerald Sadoff et al. · JAMA · 2021 · 336 citations · Full text

, , +17

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev et al. · medRxiv · 2020 · 141 citations · Full text

, , +16

The effect of personalization on response rates and data quality in web surveys

Dirk Heerwegh, Tim Vanhove, Koen Matthijs et al. · International Journal of Social Research Methodology · 2005 · 132 citations

, , +14

1–5 of 38